United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Can Japanese patent leverage strengthen Annamycin’s hand in AML? Moleculin Biotech secures Japanese patent for Annamycin. Explore how this IP move could shape AML strategy and global commercialization plans. bySoujanya RaviFebruary 20, 2026